These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

106 related articles for article (PubMed ID: 1478338)

  • 1. Introduction to the issues: appropriate methods of process validation.
    Scribner CL
    Dev Biol Stand; 1992; 76():213-4. PubMed ID: 1478338
    [No Abstract]   [Full Text] [Related]  

  • 2. Introduction to the issues: recently developed methods for characterizing cell lines.
    Kozak RW
    Dev Biol Stand; 1992; 76():21-4. PubMed ID: 1478337
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Genetic and biochemical factors affecting product consistency: introduction to the issues.
    Seamon KB
    Dev Biol Stand; 1992; 76():63-7. PubMed ID: 1478357
    [No Abstract]   [Full Text] [Related]  

  • 4. Introduction to the issues: viral vectors and potential problems in their use.
    Klinman DM
    Dev Biol Stand; 1992; 76():299-300. PubMed ID: 1478347
    [No Abstract]   [Full Text] [Related]  

  • 5. International Conference on Harmonisation; guidance on viral safety evaluation of biotechnology products derived from cell lines of human or animal origin; availability--FDA. Notice.
    Fed Regist; 1998 Sep; 63(185):51074-84. PubMed ID: 10185809
    [TBL] [Abstract][Full Text] [Related]  

  • 6. International Conference on Harmonisation; guidance on quality of biotechnological/biological products: derivation and characterization of cell substrates used for production of biotechnological/biological products; availability. Notice. Food and Drug Administration, HHS.
    Fed Regist; 1998 Sep; 63(182):50244-9. PubMed ID: 12269373
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Well-characterized biotechnology products: evolving to meet the needs of the 21st century.
    Zoon KC
    Dev Biol Stand; 1998; 96():3-8. PubMed ID: 9890510
    [No Abstract]   [Full Text] [Related]  

  • 8. CBER status on reform initiatives: industry reactions and comments.
    Page M
    Food Drug Law J; 1997; 52(2):193-6. PubMed ID: 10557559
    [No Abstract]   [Full Text] [Related]  

  • 9. Definition of a well-characterized biotechnology product.
    Zoon K; Garnick R
    Dev Biol Stand; 1998; 96():191-7. PubMed ID: 9890531
    [No Abstract]   [Full Text] [Related]  

  • 10. Bills target biosimilar drugs.
    Wadman M
    Nature; 2009 Mar; 458(7237):394-5. PubMed ID: 19325595
    [No Abstract]   [Full Text] [Related]  

  • 11. International Conference on Harmonisation; guidance on specifications: test procedures and acceptance criteria for biotechnological/biological products. Notice. Food and Drug Administration, HHS.
    Fed Regist; 1999 Aug; 64(159):44928-35. PubMed ID: 12356094
    [TBL] [Abstract][Full Text] [Related]  

  • 12. US biotech prepares to fight generic biologics.
    Reid B
    Nat Biotechnol; 2002 Apr; 20(4):322. PubMed ID: 11923820
    [No Abstract]   [Full Text] [Related]  

  • 13. Current regulatory and legal considerations for follow-on biologics.
    Kingham RF; Lietzan E
    Clin Pharmacol Ther; 2008 Nov; 84(5):633-5. PubMed ID: 18716615
    [No Abstract]   [Full Text] [Related]  

  • 14. Medical devices of human origin.
    Williams D
    Med Device Technol; 2001 Apr; 12(3):8, 10-1. PubMed ID: 11547687
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Introduction to the issues: new potential contaminants and other exogenous agents.
    Albrecht P
    Dev Biol Stand; 1992; 76():255-8. PubMed ID: 1478344
    [No Abstract]   [Full Text] [Related]  

  • 16. Compliance with Good Manufacturing Practices for facilities engaged in vector production, cell isolation, and genetic manipulations.
    Steel MP; Roessler BJ
    Curr Opin Biotechnol; 1999 Jun; 10(3):295-7. PubMed ID: 10361080
    [No Abstract]   [Full Text] [Related]  

  • 17. Regulating biotechnology licensed products.
    Hill DE
    J Parenter Sci Technol; 1989; 43(3):139-41. PubMed ID: 2732852
    [No Abstract]   [Full Text] [Related]  

  • 18. Biologicals and vaccines: regulatory perspectives.
    Petricciani JC
    Dev Biol Stand; 1986; 63():15-9. PubMed ID: 3743903
    [TBL] [Abstract][Full Text] [Related]  

  • 19. "Regulation of biological products".
    Fehnel PO
    Proc Inst Med Chic; 1972 Nov; 29(6):220. PubMed ID: 4678553
    [No Abstract]   [Full Text] [Related]  

  • 20. Philosophy and goals of validation for biotech products and the relevance of scale.
    Hageman TC
    Dev Biol Stand; 1992; 76():231-7. PubMed ID: 1478341
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.